What if you could anticipate the outcome of clinical trials months ahead of time? Our new platform, STAT Trials Pulse, helps you do just that by surfacing important changes across clinicaltrials.gov, scientific papers, and company announcements, uncovering hidden patterns in drug development activity. Start your free 30-day trial today. TRY NOW Recognizing red flags months before Summit's unfavorable results In September 2021, STAT Trials Pulse surfaced irregular activity for two pivotal studies in Summit Therapeutics' ridinilazole program, signaling red flags months before their unfavorable results were publicly announced and a subsequent 49 percent drop in Summit's stock price.  To get early signals like this about the companies, drugs, and diseases you want to monitor, start your 30-day free trial. | 
No comments